Literature DB >> 4009116

Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells.

G Schulz, L K Staffileno, R A Reisfeld, G Dennert.   

Abstract

The simultaneous injection of monoclonal antibody 9.2.27, directed against a chondroitin sulfate proteoglycan preferentially expressed on human melanoma cells, and 2 X 10(7) mononuclear splenocytes, eradicated established, progressively growing human melanoma tumors in nude mice. Neither splenocytes nor antibody alone achieved significant tumor regression. The cells responsible for tumor elimination are most likely natural killer (NK) cells: they are present in splenocytes of T cell-deficient nude mice, and cloned cells with NK activity are able to suppress tumor growth. Moreover, splenocytes treated with anti-asialo GM1 and complement or harvested from NK-deficient C57BL/6 beige mice did not cause tumor rejection. Furthermore, treatment of BALB/c nude mice just before injection with anti-asialo GM1 antiserum, which is known to eliminate NK activity in vivo, resulted in better tumor growth. In addition, evidence is presented that cells with NK activity are probably the effectors responsible for melanoma target cell lysis in vitro: Antibody-dependent and -independent cell-mediated lysis of M21 melanoma cells was suppressed when splenocytes were preincubated with complement and antibodies specific for cell surface antigens of NK cells, i.e., anti-asialo GM1, anti-Qa5, and anti-NK1.1. Moreover, splenocytes of C57BL/6 beige mice were not able to lyse M21 cells in vitro. These results strongly support the conclusion that cells with NK activity are indeed responsible for the antibody-dependent destruction of M21 melanoma cells in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4009116      PMCID: PMC2187636          DOI: 10.1084/jem.161.6.1315

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  The beige mutation in the mouse. II. Selectivity of the natural killer (NK) cell defect.

Authors:  J C Roder; M L Lohmann-Matthes; W Domzig; H Wigzell
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

2.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

3.  Evidence that natural cytotoxicity and antibody-dependent cellular cytotoxicity are mediated in humans by the same effector cell populations.

Authors:  M O de Landazuri; A Silva; J Alvarez; R B Herberman
Journal:  J Immunol       Date:  1979-07       Impact factor: 5.422

4.  Correlation between natural and antibody-dependent cell-mediated cytotoxicity against tumor targets in the mouse. I. Distribution of the reactivity.

Authors:  A Santoni; R B Herberman; H T Holden
Journal:  J Natl Cancer Inst       Date:  1979-01       Impact factor: 13.506

5.  Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.

Authors:  D M Herlyn; Z Steplewski; M F Herlyn; H Koprowski
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

6.  The beige mutation in the mouse. I. A stem cell predetermined impairment in natural killer cell function.

Authors:  J C Roder
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

7.  Therapy of mouse lymphoma with monoclonal antibodies to glycolipid: selection of low antigenic variants in vivo.

Authors:  W W Young; S I Hakomori
Journal:  Science       Date:  1981-01-30       Impact factor: 47.728

8.  Natural killer cells may be the only cells in normal mouse lymphoid cell populations endowed with cytolytic ability for antibody-coated tumour target cells.

Authors:  E Ojo; H Wigzell
Journal:  Scand J Immunol       Date:  1978-04       Impact factor: 3.487

9.  Antigenic profile of murine natural killer cells.

Authors:  G C Koo; J B Jacobson; G J Hammerling; U Hammerling
Journal:  J Immunol       Date:  1980-09       Impact factor: 5.422

10.  Tumor necrosis serum induces a serologically distinct population of NK cells.

Authors:  M Chun; V Pasanen; U Hämmerling; G F Hämmerling; M K Hoffmann
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

View more
  15 in total

1.  Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Authors:  Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma.

Authors:  H Mellstedt; J E Frödin; P Ragnhammar; G Masucci; J Shetye; B Christensson; P Biberfeld; J Makower; P Pihlstedt; B Cedermark
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Modification of regression of virally xenogenized tumor cells by cyclophosphamide and busulfan.

Authors:  K Morikawa; J Hamada; T Itaya; M Ishikawa; N Takeichi; M Hosokawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys.

Authors:  P Chattopadhyay; J Starkey; W J Morrow; S Raychaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

5.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  G Masucci; P Wersäll; P Ragnhammar; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Cross linking of anti-B16 melanoma monoclonal antibodies to lymphokine activated killer (LAK) cells: possible role in the therapy of B16 melanoma.

Authors:  A Eisenthal; S A Rosenberg
Journal:  Clin Exp Metastasis       Date:  1988 Sep-Oct       Impact factor: 5.150

8.  Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8.

Authors:  I Bergman; E Arbit; M Rosenblum; S M Larson; G Heller; N K Cheung
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

9.  Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis.

Authors:  D A Cheresh; C J Honsik; L K Staffileno; G Jung; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.

Authors:  C F Scott; V S Goldmacher; J M Lambert; R V Chari; S Bolender; M N Gauthier; W A Blättler
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.